Ahead of FDA decision, Alnylam faces the big question: Can it make money?news2025-03-19T15:24:19+00:00March 19th, 2025|Endpoints News|
Inside Pepper, a New York health tech professional communitynews2025-03-13T13:00:36+00:00March 13th, 2025|Endpoints News|
Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’news2025-02-28T12:00:38+00:00February 28th, 2025|Endpoints News|
Bayer CEO Bill Anderson previews 2025 turnaround plansnews2025-02-27T15:00:32+00:00February 27th, 2025|Endpoints News|
Biotech is still trying to make CRISPR a successnews2025-02-19T15:00:35+00:00February 19th, 2025|Endpoints News|
Drugmakers seize on biomarkers to test the FDA’s rare disease shiftnews2025-02-03T15:52:29+00:00February 3rd, 2025|Endpoints News|
China’s drug development explosion forces a US biotech reckoningnews2025-01-21T15:30:24+00:00January 21st, 2025|Endpoints News|
Broad Institute paper offers potential new framework for treating Huntington’s diseasenews2025-01-16T16:00:44+00:00January 16th, 2025|Endpoints News|
Employee lawsuit over J&J’s own health costs may loosen PBMs’ gripnews2024-12-17T14:30:14+00:00December 17th, 2024|Endpoints News|
Isomorphic Labs CEO Demis Hassabis bets on biotech’s AI futurenews2024-12-12T15:00:00+00:00December 12th, 2024|Endpoints News|
